New antibody drug takes on tough blood cancers
NCT ID NCT05787496
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve survival. The study was terminated after enrolling 28 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NC525 (a monoclonal antibody targeting LAIR-1)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced blood cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, so it is unknown if NC525 will effectively treat the disease. The trial was terminated, meaning results may be limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
New York, New York, 10022, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a menin-blocking drug outsmart stubborn leukemia?
- New drug BR108 tested in blood cancer patients – early results uncertain
- New hope for tough leukemia: first human trial of KK2845 begins
- Experimental drug cocktail targets relapsed leukemia
- Supercharged immune cells take on resistant blood cancers